25
Participants
Start Date
January 31, 2015
Primary Completion Date
January 1, 2026
Study Completion Date
December 31, 2027
Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
RECRUITING
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Lead Sponsor
Connor's Cure
OTHER
National Cancer Institute (NCI)
NIH
James Felker
OTHER